Mode
Text Size
Log in / Sign up
N/A N=115 Randomized Single-blind Treatment

Effects of Cardiac Rehabilitation (CR) on Functional Capacity and Cardiovascular Risk Factors

Cardiovascular Disease · Coronary Disease

Enrolled (actual)
115
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test — 488.1; 464.8; 394.0 meters

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
comprehensive CR (Behavioral); exercise-based CR (Other); wait list control (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Federal University of Minas Gerais
Primary completion
Oct 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test
488.1; 464.8; 394.0
SECONDARY
Risk Factors Measurement of Systolic Blood Pressure
114.6; 114.4; 120.0
SECONDARY
Risk Factors Measurement of Waist Circumference.
95.5; 93.0; 94.9
SECONDARY
Risk Factors Measurement of Fasting Blood Glucose Values
99.8; 98.8; 94.2
SECONDARY
Risk Factors Measurement of Total Cholesterol Values.
150.6; 169.3; 153.1

Summary

The purpose of this trial are to pragmatically investigate whether participation in a comprehensive CR (i.e., exercise with education) program in a Latin American MIC results in better functional capacity, cardiovascular risk factor control, health behavior, disease-related knowledge, depressive symptoms and lower mortality when compared exercise only CR or wait list control.

Eligibility Criteria

Inclusion Criteria

  • patients older than 18 years old
  • patients living in the Belo Horizonte area

Exclusion Criteria

  • any comorbid physical or serious mental condition which would interfere with the ability to exercise according to CR clinical practice guidelines (i.e., heart failure with ejection fraction less than 45%, complex ventricular dysrhythmia, advanced dementia, leg amputation, advanced cancer, disabling stroke, Parkinson's or substance dependence), and
  • any visual or cognitive condition which would preclude the participant from completing the questionnaires.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02575976). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search